Clinical Trials

50 enrolled

Nasopharyngeal Carcinoma

NCT06029270 2026-03-18

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

156 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT05524168 2026-01-15

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

41 enrolled

Nasopharyngeal Carcinoma

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

53 enrolled

Nasopharyngeal Carcinoma

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

10 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT03984357 2025-07-17

PLATINUM

152 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

100 enrolled

Nasopharyngeal Carcinoma

NCT04736810 2025-03-07

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

28 enrolled

Nasopharyngeal Carcinoma

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

47 enrolled

Nasopharyngeal Carcinoma

NCT06323239 2024-08-20

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

148 enrolled

Nasopharyngeal Carcinoma

NCT06019130 2024-05-16

NPC-Nivo

57 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06364826 2024-04-15

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

60 enrolled

Nasopharyngeal Carcinoma

NCT06331845 2024-03-26

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

39 enrolled

Nasopharyngeal Carcinoma

NCT05097209 2023-03-23

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

200 enrolled

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT05563480 2022-12-01

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

90 enrolled

Nasopharyngeal Carcinoma

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT04447612 2020-06-25

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

118 enrolled

Nasopharyngeal Carcinoma

NCT02789189 2019-09-06

Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail

Phase 2 Terminated

60 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT01309633 2019-07-22

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

80 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT00697905 2014-11-21

Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma

18 enrolled

Nasopharyngeal Carcinoma

NCT01417390 2014-03-07

Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

80 enrolled

Nasopharyngeal Carcinoma

NCT01655628 2012-08-02

GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

40 enrolled